Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1

Interventions

Bevacizumab 67atezolizumab 53durvalumab 43lenvatinib 42Nivolumab 38pembrolizumab 35tremelimumab 29Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × penpulimab × 1 year × Clear all
NCT07075419 2025-07-20

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

West China Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡